Last reviewed · How we verify
GTU®-multiHIV B clade
At a glance
| Generic name | GTU®-multiHIV B clade |
|---|---|
| Also known as | 4.0mg GTU®-multiHIV B clade |
| Sponsor | Imperial College London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo (PHASE1, PHASE2)
- Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GTU®-multiHIV B clade CI brief — competitive landscape report
- GTU®-multiHIV B clade updates RSS · CI watch RSS
- Imperial College London portfolio CI